Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309446743> ?p ?o ?g. }
- W4309446743 endingPage "627" @default.
- W4309446743 startingPage "616" @default.
- W4309446743 abstract "This study aims to assess subclinical changes in functional and morphologic myocardial MR parameters very early into a repetitive high-dose anthracycline treatment (planned cumulative dose >650 mg/m2 ), which may predict subsequent development of anthracycline-induced cardiomyopathy (aCMP).Thirty sarcoma patients with previous exposition of 300-360 mg/m2 doxorubicin-equivalent chemotherapy who were planned for a second treatment of anthracycline-based chemotherapy (360 mg/m2 doxorubicin-equivalent) were recruited. Enrolled individuals received three CMR studies (before treatment, 48 h after first anthracycline treatment and upon completion of treatment). Native T1 mapping (MOLLI 5s(3s)3s), T2 mapping, and extracellular volume (ECV) maps were acquired in addition to a conventional CMR with SSFP-cine imaging at 1.5 T. Patients were given 0.2 mmol/kg gadoteridol for ECV quantification and LGE imaging. Blood samples for cardiac biomarkers were obtained before each scan. Development of relevant aCMP was defined as drop of left ventricular ejection fraction (LVEF) by >10% compared with baseline.Twenty-three complete datasets were available for analysis. Median treatment time was 20.7 ± 3.0 weeks. Eight patients developed aCMP with LVEF reduction >10% until end of chemotherapy. Baseline LVEF was not different between patients with and without subsequent aCMP. Patients with aCMP had decreased LV mass upon completion of therapy (99.4 ± 26.5 g vs. 90.3 ± 24.8 g; P = 0.02), whereas patients without aCMP did not show a change in LV mass (91.5 ± 20.0 g vs. 89.0 ± 23.6 g; P > 0.05). On strain analysis, GLS (-15.3 ± 1.3 vs. -13.4 ± 1.6; P = 0.02) and GCS (-16.7 ± 2.1 vs. -14.9 ± 2.6; P = 0.04) were decreased in aCMP patients upon completion of therapy, whereas non-aCMP individuals showed no change in GLS (-15.4 ± 3.3 vs. -15.4 ± 3.4; P = 0.97). When assessed 48 h after first dose of anthracyclines, patients with subsequent aCMP had significantly elevated myocardial T2 times compared with before therapy (53.0 ± 2.8 ms vs. 49.3 ± 5.2 ms, P = 0.02) than patients who did not develop aCMP (50.7 ± 5.1 ms vs. 51.1 ± 3.9 ms, P > 0.05). Native T1 times decreased at 48 h after first dose irrespective of development of subsequent aCMP (1020.2 ± 28.4 ms vs. 973.5 ± 40.3 ms). Upon completion of therapy, patients with aCMP had increased native T1 compared with baseline (1050.8 ± 17.9 ms vs. 1022.4 ± 22.0 ms; P = 0.01), whereas non-aCMP patients did not (1034.5 ± 46.6 ms vs. 1018.4 ± 29.7 ms; P = 0.15). No patient developed new myocardial scars or compact myocardial fibrosis under chemotherapy. Cardiac biomarkers were elevated independent of development of aCMP.With high cumulative anthracycline doses, early increase of T2 times 48 h after first treatment with anthracyclines can predict the development of subsequent aCMP after completion of chemotherapy. Early drop of native T1 times occurs irrespective of development of aCMP in high-dose anthracycline therapy." @default.
- W4309446743 created "2022-11-28" @default.
- W4309446743 creator A5006795895 @default.
- W4309446743 creator A5010942787 @default.
- W4309446743 creator A5020195438 @default.
- W4309446743 creator A5021108105 @default.
- W4309446743 creator A5032361891 @default.
- W4309446743 creator A5048170384 @default.
- W4309446743 creator A5065800279 @default.
- W4309446743 date "2022-11-20" @default.
- W4309446743 modified "2023-10-01" @default.
- W4309446743 title "Early myocardial oedema can predict subsequent cardiomyopathy in high‐dose anthracycline therapy" @default.
- W4309446743 cites W1492360552 @default.
- W4309446743 cites W1949633840 @default.
- W4309446743 cites W1973297032 @default.
- W4309446743 cites W2037706689 @default.
- W4309446743 cites W2068483637 @default.
- W4309446743 cites W2082743257 @default.
- W4309446743 cites W2084817232 @default.
- W4309446743 cites W2087954557 @default.
- W4309446743 cites W2131098741 @default.
- W4309446743 cites W2136545216 @default.
- W4309446743 cites W2157806784 @default.
- W4309446743 cites W2167777123 @default.
- W4309446743 cites W2279656465 @default.
- W4309446743 cites W2412263508 @default.
- W4309446743 cites W2468012411 @default.
- W4309446743 cites W2553544962 @default.
- W4309446743 cites W2571120626 @default.
- W4309446743 cites W2594448454 @default.
- W4309446743 cites W2597196803 @default.
- W4309446743 cites W2616481950 @default.
- W4309446743 cites W2736563004 @default.
- W4309446743 cites W2746808953 @default.
- W4309446743 cites W2757698096 @default.
- W4309446743 cites W2800029818 @default.
- W4309446743 cites W2886753114 @default.
- W4309446743 cites W2888073419 @default.
- W4309446743 cites W2888658020 @default.
- W4309446743 cites W2892487169 @default.
- W4309446743 cites W2916365489 @default.
- W4309446743 cites W2921120754 @default.
- W4309446743 cites W3034421650 @default.
- W4309446743 cites W3040275902 @default.
- W4309446743 cites W3109544852 @default.
- W4309446743 cites W3166711533 @default.
- W4309446743 cites W3169574745 @default.
- W4309446743 cites W4309446743 @default.
- W4309446743 doi "https://doi.org/10.1002/ehf2.14232" @default.
- W4309446743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36404640" @default.
- W4309446743 hasPublicationYear "2022" @default.
- W4309446743 type Work @default.
- W4309446743 citedByCount "2" @default.
- W4309446743 countsByYear W43094467432022 @default.
- W4309446743 countsByYear W43094467432023 @default.
- W4309446743 crossrefType "journal-article" @default.
- W4309446743 hasAuthorship W4309446743A5006795895 @default.
- W4309446743 hasAuthorship W4309446743A5010942787 @default.
- W4309446743 hasAuthorship W4309446743A5020195438 @default.
- W4309446743 hasAuthorship W4309446743A5021108105 @default.
- W4309446743 hasAuthorship W4309446743A5032361891 @default.
- W4309446743 hasAuthorship W4309446743A5048170384 @default.
- W4309446743 hasAuthorship W4309446743A5065800279 @default.
- W4309446743 hasBestOaLocation W43094467431 @default.
- W4309446743 hasConcept C113280763 @default.
- W4309446743 hasConcept C121608353 @default.
- W4309446743 hasConcept C126322002 @default.
- W4309446743 hasConcept C151032500 @default.
- W4309446743 hasConcept C164705383 @default.
- W4309446743 hasConcept C2776694085 @default.
- W4309446743 hasConcept C2776802502 @default.
- W4309446743 hasConcept C2778198053 @default.
- W4309446743 hasConcept C2778233292 @default.
- W4309446743 hasConcept C2778797674 @default.
- W4309446743 hasConcept C2781303535 @default.
- W4309446743 hasConcept C530470458 @default.
- W4309446743 hasConcept C71924100 @default.
- W4309446743 hasConcept C78085059 @default.
- W4309446743 hasConceptScore W4309446743C113280763 @default.
- W4309446743 hasConceptScore W4309446743C121608353 @default.
- W4309446743 hasConceptScore W4309446743C126322002 @default.
- W4309446743 hasConceptScore W4309446743C151032500 @default.
- W4309446743 hasConceptScore W4309446743C164705383 @default.
- W4309446743 hasConceptScore W4309446743C2776694085 @default.
- W4309446743 hasConceptScore W4309446743C2776802502 @default.
- W4309446743 hasConceptScore W4309446743C2778198053 @default.
- W4309446743 hasConceptScore W4309446743C2778233292 @default.
- W4309446743 hasConceptScore W4309446743C2778797674 @default.
- W4309446743 hasConceptScore W4309446743C2781303535 @default.
- W4309446743 hasConceptScore W4309446743C530470458 @default.
- W4309446743 hasConceptScore W4309446743C71924100 @default.
- W4309446743 hasConceptScore W4309446743C78085059 @default.
- W4309446743 hasIssue "1" @default.
- W4309446743 hasLocation W43094467431 @default.
- W4309446743 hasLocation W43094467432 @default.
- W4309446743 hasLocation W43094467433 @default.
- W4309446743 hasLocation W43094467434 @default.
- W4309446743 hasOpenAccess W4309446743 @default.